TD Cowen analyst Marc Frahm initiates coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating.The analyst comments "Nektar is ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage